San Diego, Calif., January 4, 2017 – Forge Therapeutics, Inc. announced today that it will present at the 9th Annual Biotech Showcase 2017 being held January 9-11, 2017 at the Hilton San Francisco Union Square, California.
Zachary Zimmerman, Ph.D., Forge Therapeutics CEO, will present an overview of the Company’s novel metalloenzyme chemistry platform and leading program targeting Gram-negative ‘superbug’ bacteria.
Date: Tuesday, January 10, 2017
Time: 11:15 AM PT
Location: Hilton San Francisco Union Square
Track: Room 9 (Ballroom Level)
To schedule a meeting with Forge Therapeutics management team at this conference contact Info@ForgeTherapeutics.com
About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit www.ForgeTherapeutics.com.